The latest price target for Repligen (NASDAQ:RGEN) was reported by Wells Fargo on August 27, 2024. The analyst firm set a price target for $180.00 expecting RGEN to rise to within 12 months (a possible 29.50% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Repligen (NASDAQ:RGEN) was provided by Wells Fargo, and Repligen initiated their overweight rating.

The last upgrade for Repligen Corp happened on June 26, 2024 when Deutsche Bank raised their price target to $155. Deutsche Bank previously had a hold for Repligen Corp.

The last downgrade for Repligen Corp happened on December 4, 2023 when Benchmark changed their price target from N/A to N/A for Repligen Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Repligen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Repligen was filed on August 27, 2024 so you should expect the next rating to be made available sometime around August 27, 2025.

While ratings are subjective and will change, the latest Repligen (RGEN) rating was a initiated with a price target of $0.00 to $180.00. The current price Repligen (RGEN) is trading at is $139.00, which is within the analyst’s predicted range.